Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer : A Safety and Efficacy Trial (SUNSET)
Copyright © 2024. Published by Elsevier Inc..
INTRODUCTION: The use of stereotactic body radiotherapy (SBRT) for tumors in close proximity to the central mediastinal structures has been associated with a high risk of toxicity. This study (BLINDED FOR REVIEW) aimed to determine the maximally tolerated dose (MTD) of SBRT for ultra-central (UC) non-small cell lung carcinoma (NSCLC), using a time-to-event continual reassessment methodology (TITE-CRM).
METHODS: Patients with T1-3N0M0 (≤ 6 cm) NSCLC were eligible. The MTD was defined as the dose of radiotherapy associated with a ≤ 30% rate of grade (G) 3-5 pre-specified treatment-related toxicity occurring within 2 years of treatment. The starting dose level was 60 Gy in 8 daily fractions. The dose-maximum hotspot was limited to 120% and within the planning tumor volume (PTV); tumors with endobronchial invasion were excluded. This primary analysis occurred two years after completion of accrual.
RESULTS: Between March 2018 and April 2021, 30 patients were enrolled at 5 institutions. The median age was 73 years (range: 65-87) and 17 (57%) were female. PTV was abutting proximal bronchial tree in 19 (63%), esophagus 5 (17%), pulmonary vein 1 (3.3%) and pulmonary artery 14 (47%). All patients received 60 Gy in 8 fractions. The median follow-up was 37 months (range: 8.9-51). Two patients (6.7%) experienced G3-5 adverse events related to treatment: 1 patient with G3 dyspnea and 1 G5 pneumonia; the latter had CT findings consistent with a background of interstitial lung disease. Three-year overall survival was 72.5% (95% confidence interval [CI]: 52.3-85.3%), progression-free survival 66.1% (95% CI: 46.1-80.2%), local control 89.6% (95% CI: 71.2-96.5%), regional control 96.4% (95% CI: 77.2-99.5%) and distant control 85.9% (95% CI: 66.7-94.5%). Quality of life scores declined numerically over time, but the decreases were not clinically or statistically significant.
CONCLUSIONS: 60 Gy in 8 fractions, planned and delivered with only a moderate hotspot, has a favorable adverse event rate within the pre-specified acceptability criteria, and results in excellent control for UC tumors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
International journal of radiation oncology, biology, physics - (2024) vom: 11. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meredith, E Giuliani [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Efficacy |
|---|
| Anmerkungen: |
Date Revised 13.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.ijrobp.2024.03.050 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371035937 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371035937 | ||
| 003 | DE-627 | ||
| 005 | 20240415232520.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240415s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijrobp.2024.03.050 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1375.xml |
| 035 | |a (DE-627)NLM371035937 | ||
| 035 | |a (NLM)38614279 | ||
| 035 | |a (PII)S0360-3016(24)00480-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Meredith, E Giuliani |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer |b A Safety and Efficacy Trial (SUNSET) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024. Published by Elsevier Inc. | ||
| 520 | |a INTRODUCTION: The use of stereotactic body radiotherapy (SBRT) for tumors in close proximity to the central mediastinal structures has been associated with a high risk of toxicity. This study (BLINDED FOR REVIEW) aimed to determine the maximally tolerated dose (MTD) of SBRT for ultra-central (UC) non-small cell lung carcinoma (NSCLC), using a time-to-event continual reassessment methodology (TITE-CRM) | ||
| 520 | |a METHODS: Patients with T1-3N0M0 (≤ 6 cm) NSCLC were eligible. The MTD was defined as the dose of radiotherapy associated with a ≤ 30% rate of grade (G) 3-5 pre-specified treatment-related toxicity occurring within 2 years of treatment. The starting dose level was 60 Gy in 8 daily fractions. The dose-maximum hotspot was limited to 120% and within the planning tumor volume (PTV); tumors with endobronchial invasion were excluded. This primary analysis occurred two years after completion of accrual | ||
| 520 | |a RESULTS: Between March 2018 and April 2021, 30 patients were enrolled at 5 institutions. The median age was 73 years (range: 65-87) and 17 (57%) were female. PTV was abutting proximal bronchial tree in 19 (63%), esophagus 5 (17%), pulmonary vein 1 (3.3%) and pulmonary artery 14 (47%). All patients received 60 Gy in 8 fractions. The median follow-up was 37 months (range: 8.9-51). Two patients (6.7%) experienced G3-5 adverse events related to treatment: 1 patient with G3 dyspnea and 1 G5 pneumonia; the latter had CT findings consistent with a background of interstitial lung disease. Three-year overall survival was 72.5% (95% confidence interval [CI]: 52.3-85.3%), progression-free survival 66.1% (95% CI: 46.1-80.2%), local control 89.6% (95% CI: 71.2-96.5%), regional control 96.4% (95% CI: 77.2-99.5%) and distant control 85.9% (95% CI: 66.7-94.5%). Quality of life scores declined numerically over time, but the decreases were not clinically or statistically significant | ||
| 520 | |a CONCLUSIONS: 60 Gy in 8 fractions, planned and delivered with only a moderate hotspot, has a favorable adverse event rate within the pre-specified acceptability criteria, and results in excellent control for UC tumors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a non-small cell lung cancer | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a stereotactic radiotherapy | |
| 650 | 4 | |a ultra-central | |
| 700 | 1 | |a Filion, Edith |e verfasserin |4 aut | |
| 700 | 1 | |a Faria, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Kundapur, Vijayananda |e verfasserin |4 aut | |
| 700 | 1 | |a Thuc, Toni Vu Thi Trinh |e verfasserin |4 aut | |
| 700 | 1 | |a Lok, Benjamin H |e verfasserin |4 aut | |
| 700 | 1 | |a Raman, Srinivas |e verfasserin |4 aut | |
| 700 | 1 | |a Bahig, Houda |e verfasserin |4 aut | |
| 700 | 1 | |a Laba, Joanna M |e verfasserin |4 aut | |
| 700 | 1 | |a Lang, Pencilla |e verfasserin |4 aut | |
| 700 | 1 | |a Louie, Alexander V |e verfasserin |4 aut | |
| 700 | 1 | |a Hope, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Rodrigues, George B |e verfasserin |4 aut | |
| 700 | 1 | |a Bezjak, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Campeau, Marie-Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Duclos, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Bratman, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Swaminath, Anand |e verfasserin |4 aut | |
| 700 | 1 | |a Salunkhe, Rohan |e verfasserin |4 aut | |
| 700 | 1 | |a Warner, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Palma, David A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of radiation oncology, biology, physics |d 1976 |g (2024) vom: 11. Apr. |w (DE-627)NLM000375381 |x 1879-355X |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:11 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijrobp.2024.03.050 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 11 |c 04 | ||